{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:03:12Z","timestamp":1791518592139,"version":"4.3.4"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.intimp.2022.108858","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:44:00Z","timestamp":1652921040000},"page":"108858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Emerging therapeutic potential of regulatory T (Treg) cells for rheumatoid arthritis: New insights and challenges"],"prefix":"10.1016","volume":"108","author":[{"given":"Fatemeh","family":"Rezaei Kahmini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Shahgaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Mansourabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2022.108858_b0005","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1007\/s13346-021-01038-w","article-title":"Biomaterial-based immunotherapeutic strategies for rheumatoid arthritis","volume":"11","author":"Tu","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"issue":"6","key":"10.1016\/j.intimp.2022.108858_b0010","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3390\/ijms20061332","article-title":"Immunopathogenic mechanisms and novel immune-modulated therapies in rheumatoid arthritis","volume":"20","author":"Chen","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2022.108858_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.655114","article-title":"Pathogenesis and function of Interleukin-35 in Rheumatoid arthritis","volume":"12","author":"Xin","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2022.108858_b0020","first-page":"1021","article-title":"Function and Role of Regulatory T Cells in Rheumatoid Arthritis","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108858_b0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41590-020-00816-x","article-title":"The immunology of rheumatoid arthritis","volume":"22","author":"Weyand","year":"2021","journal-title":"Nat. immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108858_b0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2177\/jsci.33.48","article-title":"Genetic background of tolerance breakdown in rheumatoid arthritis","volume":"33","author":"Kochi","year":"2010","journal-title":"Japanese journal of clinical immunology."},{"key":"10.1016\/j.intimp.2022.108858_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00279","article-title":"Heat shock proteins can be surrogate autoantigens for induction of antigen specific therapeutic tolerance in rheumatoid arthritis","volume":"10","author":"van Eden","year":"2019","journal-title":"Front. immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108858_b0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.smim.2011.07.004","article-title":"Therapeutic potential of Tregs to treat rheumatoid arthritis","volume":"23","author":"Wright","year":"2011","journal-title":"Semin. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108858_b0045","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"10086","key":"10.1016\/j.intimp.2022.108858_b0050","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"The Lancet."},{"issue":"9","key":"10.1016\/j.intimp.2022.108858_b0055","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s11926-013-0352-0","article-title":"Treg cells in rheumatoid arthritis: an update","volume":"15","author":"Cooles","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"issue":"3","key":"10.1016\/j.intimp.2022.108858_b0060","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/08923973.2018.1437625","article-title":"CRISPR and personalized Treg therapy: new insights into the treatment of rheumatoid arthritis","volume":"40","author":"Safari","year":"2018","journal-title":"Immunopharmacol. immunotoxicol."},{"key":"10.1016\/j.intimp.2022.108858_b0065","article-title":"Genetic approaches for the diagnosis and treatment of rheumatoid arthritis through personalized medicine","volume":"23","author":"Qamar","year":"2021","journal-title":"Gene. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2022.108858_b0070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cclet.2020.11.048","article-title":"Nanotechnology for diagnosis and therapy of rheumatoid arthritis: Evolution towards theranostic approaches","volume":"32","author":"Zhao","year":"2021","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.intimp.2022.108858_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/963748","article-title":"Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis","volume":"2013","author":"Buc","year":"2013","journal-title":"Mediators Inflamm."},{"issue":"3","key":"10.1016\/j.intimp.2022.108858_b0080","doi-asserted-by":"crossref","first-page":"102761","DOI":"10.1016\/j.autrev.2021.102761","article-title":"Engineered antigen-specific regulatory T cells for autoimmune skin conditions","volume":"20","author":"Mukhatayev","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2022.108858_b0085","first-page":"814","article-title":"Emerging Therapeutic Strategies to Restore Regulatory T Cell Control of Islet Autoimmunity in Type 1 Diabetes","volume":"12","author":"Volfson-Sedletsky","year":"2021","journal-title":"Fron. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2022.108858_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-016-0616-6","article-title":"Regulatory T cells in SLE: biology and use in treatment","volume":"18","author":"Giang","year":"2016","journal-title":"Curr. rheumatol. rep."},{"issue":"10","key":"10.1016\/j.intimp.2022.108858_b0095","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1600-0463.2004.apm1121001.x","article-title":"CD4+ CD25+ regulatory T cells: I. Phenotype and physiology","volume":"112","author":"Holm","year":"2004","journal-title":"Apmis."},{"issue":"6","key":"10.1016\/j.intimp.2022.108858_b0100","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1096\/fj.11-193672","article-title":"Naturally occurring regulatory T cells: markers, mechanisms, and manipulation","volume":"26","author":"Schmetterer","year":"2012","journal-title":"FASEB. J."},{"issue":"3","key":"10.1016\/j.intimp.2022.108858_b0105","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.4049\/jimmunol.167.3.1245","article-title":"CD4+ CD25high regulatory cells in human peripheral blood","volume":"167","author":"Baecher-Allan","year":"2001","journal-title":"J. Immunol."},{"issue":"Suppl 2","key":"10.1016\/j.intimp.2022.108858_b0110","doi-asserted-by":"crossref","first-page":"i96","DOI":"10.1136\/annrheumdis-2011-200588","article-title":"Roles of LAG3 and EGR2 in regulatory T cells","volume":"71","author":"Okamura","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2022.108858_b0115","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.21.120601.141122","article-title":"Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses","volume":"22","author":"Sakaguchi","year":"2004","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108858_b0120","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"issue":"26","key":"10.1016\/j.intimp.2022.108858_b0125","doi-asserted-by":"crossref","first-page":"10468","DOI":"10.1073\/pnas.1201131109","article-title":"Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo","volume":"109","author":"Gotot","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.intimp.2022.108858_b0130","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nri2343","article-title":"How regulatory T cells work","volume":"8","author":"Vignali","year":"2008","journal-title":"Nat. rev. immunol."},{"key":"10.1016\/j.intimp.2022.108858_b0135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fimmu.2012.00051","article-title":"Molecular mechanisms of treg-mediated T cell suppression","volume":"3","author":"Schmidt","year":"2012","journal-title":"Front. immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108858_b0140","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2567.2008.02813.x","article-title":"Mechanisms of regulatory T-cell suppression\u2013a diverse arsenal for a moving target","volume":"124","author":"Sojka","year":"2008","journal-title":"Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108858_b0145","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/cmi.2013.2","article-title":"Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy","volume":"10","author":"Pedroza-Pacheco","year":"2013","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2022.108858_b0150","series-title":"Natural Killer Cells","first-page":"329","article-title":"Interactions between NK cells and regulatory T cells, in Natural Killer Cells","author":"Terme","year":"2010"},{"issue":"49","key":"10.1016\/j.intimp.2022.108858_b0155","doi-asserted-by":"crossref","first-page":"19446","DOI":"10.1073\/pnas.0706832104","article-title":"CD4+ CD25+ Foxp3+ regulatory T cells induce alternative activation of human monocytes\/macrophages","volume":"104","author":"Tiemessen","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2022.108858_b0160","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/eji.201444486","article-title":"Autoimmune priming, tissue attack and chronic inflammation\u2014T he three stages of rheumatoid arthritis","volume":"44","author":"Holmdahl","year":"2014","journal-title":"Euro. j. immunol."},{"issue":"23","key":"10.1016\/j.intimp.2022.108858_b0165","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2022.108858_b0170","first-page":"68","article-title":"Th1-Th17 ratio as a new insight in rheumatoid arthritis disease","author":"Bazzazi","year":"2018","journal-title":"Iran. J. Allergy. Asthma. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.108858_b0175","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrrheum.2016.132","article-title":"The inflammatory role of phagocyte apoptotic pathways in rheumatic diseases","volume":"12","author":"Cuda","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2022.108858_b0180","first-page":"93","article-title":"The Th1\/Th2 cytokine balance in arthritis","author":"Miossec","year":"1998","journal-title":"T Cells in Arthritis."},{"key":"10.1016\/j.intimp.2022.108858_b0185","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaut.2017.12.006","article-title":"Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis","volume":"87","author":"van Hamburg","year":"2018","journal-title":"J. autoimmun."},{"issue":"4","key":"10.1016\/j.intimp.2022.108858_b0190","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s10875-011-9540-8","article-title":"Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis","volume":"31","author":"Zhang","year":"2011","journal-title":"J. clin. immunol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108858_b0195","doi-asserted-by":"crossref","first-page":"e31000","DOI":"10.1371\/journal.pone.0031000","article-title":"Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.108858_b0200","article-title":"The distinct role of Tfh and Th17 cells and their interplay in the pathogenesis of rheumatoid arthritis","author":"Zhang","year":"2017","journal-title":"Am Assoc Immnol."},{"key":"10.1016\/j.intimp.2022.108858_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/6894374","article-title":"T-cell subsets in rheumatoid arthritis patients on long-term anti-TNF or IL-6 receptor blocker therapy","volume":"2017","author":"Dulic","year":"2017","journal-title":"Med. inflam."},{"issue":"6","key":"10.1016\/j.intimp.2022.108858_b0210","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00109-011-0841-4","article-title":"IL-17 producing T cells in mouse models of multiple sclerosis and rheumatoid arthritis","volume":"90","author":"P\u00f6llinger","year":"2012","journal-title":"J. molecul. med."},{"issue":"4","key":"10.1016\/j.intimp.2022.108858_b0215","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10875-011-9542-6","article-title":"Combined treatment of etanercept and MTX reverses Th1\/Th2, Th17\/Treg imbalance in patients with rheumatoid arthritis","volume":"31","author":"Lina","year":"2011","journal-title":"J. Clinic. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2022.108858_b0220","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.3899\/jrheum.110283","article-title":"CD4+ CD25highCD127low\/-Treg cell frequency from peripheral blood correlates with disease activity in patients with rheumatoid arthritis","volume":"38","author":"Kawashiri","year":"2011","journal-title":"J. Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108858_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar1192","article-title":"CD25 bright CD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease","volume":"6","author":"Cao","year":"2004","journal-title":"Arthritis Res Ther."},{"issue":"2","key":"10.1016\/j.intimp.2022.108858_b0230","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1365-2249.2005.02754.x","article-title":"CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis","volume":"140","author":"M\u00f6tt\u00f6nen","year":"2005","journal-title":"Clinic. Experi. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108858_b0235","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/immu.200390024","article-title":"Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis","volume":"33","author":"Cao","year":"2003","journal-title":"Euro. J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108858_b0240","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.20040165","article-title":"Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF\u03b1 therapy","volume":"200","author":"Ehrenstein","year":"2004","journal-title":"J. Exper. Med."},{"issue":"4","key":"10.1016\/j.intimp.2022.108858_b0245","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1007\/s10753-017-0577-6","article-title":"Tim3+ Foxp3+ Treg cells are potent inhibitors of effector T cells and are suppressed in rheumatoid arthritis","volume":"40","author":"Sun","year":"2017","journal-title":"Inflammation."},{"issue":"7","key":"10.1016\/j.intimp.2022.108858_b0250","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","article-title":"Regulatory T cells in autoimmune disease","volume":"19","author":"Dominguez-Villar","year":"2018","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108858_b0255","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-7-89","article-title":"Human T cells express CD25 and Foxp3 upon activation and exhibit effector\/memory phenotypes without any regulatory\/suppressor function","volume":"7","author":"Kmieciak","year":"2009","journal-title":"J. Trans. Med."},{"issue":"5","key":"10.1016\/j.intimp.2022.108858_b0260","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.immuni.2009.05.001","article-title":"Plasticity of CD4+ T cell lineage differentiation","volume":"30","author":"Zhou","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2022.108858_b0265","unstructured":"M. Cosentino, Caratterizzazione del trasportatore vescicolare di tipo 2 nei linfociti umani."},{"issue":"10","key":"10.1016\/j.intimp.2022.108858_b0270","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1002\/art.30503","article-title":"Impaired suppression of synovial fluid CD4+ CD25\u2212 T cells from patients with juvenile idiopathic arthritis by CD4+ CD25+ Treg cells","volume":"63","author":"Haufe","year":"2011","journal-title":"Arthritis. Rheum."},{"issue":"9","key":"10.1016\/j.intimp.2022.108858_b0275","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1002\/art.20499","article-title":"CD4+ CD25+ regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid","volume":"50","author":"van Amelsfort","year":"2004","journal-title":"Arthritis. Rheum."},{"issue":"3","key":"10.1016\/j.intimp.2022.108858_b0280","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/art.37832","article-title":"Interaction with activated monocytes enhances cytokine expression and suppressive activity of human CD4+ CD45RO+ CD25+ CD127low regulatory T cells","volume":"65","author":"Walter","year":"2013","journal-title":"Arthritis. Rheum."},{"issue":"1","key":"10.1016\/j.intimp.2022.108858_b0285","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00439-005-0033-9","article-title":"Meta-analysis of the association of CTLA-4 exon-1+ 49A\/G polymorphism with rheumatoid arthritis","volume":"118","author":"Han","year":"2005","journal-title":"Hu. Gene."},{"issue":"49","key":"10.1016\/j.intimp.2022.108858_b0290","doi-asserted-by":"crossref","first-page":"19396","DOI":"10.1073\/pnas.0806855105","article-title":"Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis","volume":"105","author":"Flores-Borja","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2022.108858_b0295","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/eji.201041004","article-title":"The inflammatory milieu in the rheumatic joint reduces regulatory T-cell function","volume":"41","author":"Herrath","year":"2011","journal-title":"Euro. J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108858_b0300","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nm.3085","article-title":"Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-\u03b1 in rheumatoid arthritis","volume":"19","author":"Nie","year":"2013","journal-title":"Nat. Med."},{"issue":"Supplement","key":"10.1016\/j.intimp.2022.108858_b0305","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1097\/01.rhu.0000130687.75646.44","article-title":"Pathogenesis of rheumatoid arthritis","volume":"10","author":"Weissmann","year":"2004","journal-title":"J. Clinic. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2022.108858_b0310","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/jnr.24073","article-title":"The role of regulatory T cells in nervous system pathologies","volume":"96","author":"Duffy","year":"2018","journal-title":"J. Neuro. Res."},{"key":"10.1016\/j.intimp.2022.108858_b0315","doi-asserted-by":"crossref","first-page":"14030","DOI":"10.1038\/mtm.2014.30","article-title":"Ex vivo expanded autologous polyclonal regulatory T cells suppress inhibitor formation in hemophilia","volume":"1","author":"Sarkar","year":"2014","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"issue":"12","key":"10.1016\/j.intimp.2022.108858_b0320","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1007\/s00018-011-0907-z","article-title":"The battle against immunopathology: infectious tolerance mediated by regulatory T cells","volume":"69","author":"Gravano","year":"2012","journal-title":"Cell. Mol. Life. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2022.108858_b0325","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.celrep.2019.12.081","article-title":"Treg-cell-derived IL-35-coated extracellular vesicles promote infectious tolerance","volume":"30","author":"Sullivan","year":"2020","journal-title":"Cell reports."},{"issue":"5","key":"10.1016\/j.intimp.2022.108858_b0330","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/cmi.2015.44","article-title":"Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance","volume":"12","author":"Zeng","year":"2015","journal-title":"Cell. Mol. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2022.108858_b0335","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nri2189","article-title":"Regulatory T cells and infection: a dangerous necessity","volume":"7","author":"Belkaid","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2022.108858_b0340","first-page":"104173","article-title":"Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3+ regulatory T cells","volume":"355","author":"Mannie","year":"2020","journal-title":"CellImmunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108858_b0345","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4049\/jimmunol.164.1.183","article-title":"Suppressor effector function of CD4+ CD25+ immunoregulatory T cells is antigen nonspecific","volume":"164","author":"Thornton","year":"2000","journal-title":"J. Immunol."},{"issue":"6411","key":"10.1016\/j.intimp.2022.108858_b0350","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.aau2688","article-title":"Treg cells\u2014the next frontier of cell therapy","volume":"362","author":"Bluestone","year":"2018","journal-title":"Science"},{"issue":"910","key":"10.1016\/j.intimp.2022.108858_b0355","first-page":"58","article-title":"Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity","volume":"143","author":"Billingham","year":"1954","journal-title":"Proc. R. Soc. B: Biol. Sci."},{"key":"10.1016\/j.intimp.2022.108858_b0360","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3389\/fcimb.2020.00395","article-title":"Harnessing natural killer cell innate and adoptive traits in HIV infection","volume":"10","author":"Alrubayyi","year":"2020","journal-title":"Front. Cell. Infec. Microbiol."},{"key":"10.1016\/j.intimp.2022.108858_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110365","article-title":"Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis","volume":"146","author":"Saadeldin","year":"2021","journal-title":"Med. Hypo."},{"issue":"9","key":"10.1016\/j.intimp.2022.108858_b0370","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","article-title":"Cancer immunotherapy with \u03b3\u03b4 T cells: many paths ahead of us","volume":"17","author":"Kabelitz","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2022.108858_b0375","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.biopha.2010.01.007","article-title":"Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+ CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines","volume":"64","author":"Xinqiang","year":"2010","journal-title":"Biomed. Pharmacother."},{"issue":"12","key":"10.1016\/j.intimp.2022.108858_b0380","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.4049\/jimmunol.177.12.8338","article-title":"Rapamycin promotes expansion of functional CD4+ CD25+ FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients","volume":"177","author":"Battaglia","year":"2006","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108858_b0385","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/cei.12017","article-title":"Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients","volume":"171","author":"Pesce","year":"2013","journal-title":"Clin. Exp. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2022.108858_b0390","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/art.34477","article-title":"Brief report: inhibition of interleukin-6 function corrects Th17\/Treg cell imbalance in patients with rheumatoid arthritis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis. Rheum."},{"issue":"5","key":"10.1016\/j.intimp.2022.108858_b0395","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","article-title":"A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)","volume":"70","author":"Quartier","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2022.108858_b0400","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/ced.13777","article-title":"Secukinumab for treatment of psoriasis: does secukinumab precipitate or promote the presentation of cutaneous T-cell lymphoma?","volume":"44","author":"Yoo","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108858_b0405","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/icb.2014.102","article-title":"A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway","volume":"93","author":"Helling","year":"2015","journal-title":"Immunol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108858_b0410","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.25058","article-title":"ANTI-CD3 therapy expands the numbers of CD4+ and CD8+ treg cells and induces sustained amelioration of collagen-induced arthritis","volume":"62","author":"Notley","year":"2010","journal-title":"Arthritis. Rheum."},{"issue":"5899","key":"10.1016\/j.intimp.2022.108858_b0415","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.108858_b0420","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.imlet.2005.06.012","article-title":"CD28 superagonists: mode of action and therapeutic potential","volume":"100","author":"H\u00fcnig","year":"2005","journal-title":"Immunol. Lett."},{"issue":"11","key":"10.1016\/j.intimp.2022.108858_b0425","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/ni.3540","article-title":"An essential role for the IL-2 receptor in T reg cell function","volume":"17","author":"Chinen","year":"2016","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108858_b0430","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3109\/08916931003782163","article-title":"Therapeutic potential of TGF-\u03b2-induced CD4+ Foxp3+ regulatory T cells in autoimmune diseases","volume":"44","author":"Zhou","year":"2011","journal-title":"Autoimmun."},{"issue":"1","key":"10.1016\/j.intimp.2022.108858_b0435","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+ CD25+ CD127\u2212 T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2022.108858_b0440","first-page":"1061","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood. Am. J. Hematol."},{"key":"10.1016\/j.intimp.2022.108858_b0445","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jaut.2016.03.011","article-title":"Regulatory T cell therapy for type 1 diabetes: May the force be with you","volume":"71","author":"Gitelman","year":"2016","journal-title":"J. Autoimmun."},{"issue":"10","key":"10.1016\/j.intimp.2022.108858_b0450","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrgastro.2012.167","article-title":"Regulatory T-cell therapy is a safe and well-tolerated potential approach for treating refractory Crohn's disease","volume":"9","author":"McLarnon","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.intimp.2022.108858_b0455","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1053\/j.gastro.2012.07.116","article-title":"Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease","volume":"143","author":"Desreumaux","year":"2012","journal-title":"Gastroenterol."},{"issue":"5748","key":"10.1016\/j.intimp.2022.108858_b0460","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/283666a0","article-title":"Immunisation against heterologous type II collagen induces arthritis in mice","volume":"283","author":"Courtenay","year":"1980","journal-title":"Nat."},{"issue":"9","key":"10.1016\/j.intimp.2022.108858_b0465","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1002\/art.22846","article-title":"Enhanced efficacy of regulatory T cell transfer against increasing resistance, by elevated Foxp3 expression induced in arthritic murine hosts","volume":"56","author":"Ohata","year":"2007","journal-title":"Arthritis. Rheum."},{"issue":"7","key":"10.1016\/j.intimp.2022.108858_b0470","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/art.21195","article-title":"Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells","volume":"52","author":"Morgan","year":"2005","journal-title":"Arthritis. Rheum."},{"issue":"35","key":"10.1016\/j.intimp.2022.108858_b0475","doi-asserted-by":"crossref","first-page":"14134","DOI":"10.1073\/pnas.1206803109","article-title":"Regulatory T cells that recognize a ubiquitous stress-inducible self-antigen are long-lived suppressors of autoimmune arthritis","volume":"109","author":"van Herwijnen","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2022.108858_b0480","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2006-01-0177","article-title":"Regulatory T-cell compartmentalization and trafficking","volume":"108","author":"Wei","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2022.108858_b0485","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1084\/jem.194.6.847","article-title":"Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4+ CD25+ regulatory T cells","volume":"194","author":"Iellem","year":"2001","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.intimp.2022.108858_b0490","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/ard.2003.017566","article-title":"Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors Ann","volume":"64","author":"Radstake","year":"2005","journal-title":"Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2022.108858_b0495","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10753-017-0704-4","article-title":"Adoptive induced antigen-specific Treg cells reverse inflammation in collagen-induced arthritis mouse model","volume":"41","author":"Sun","year":"2018","journal-title":"Inflammation."},{"key":"10.1016\/j.intimp.2022.108858_b0500","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3389\/fonc.2014.00209","article-title":"Utilizing regulatory T cells against rheumatoid arthritis","volume":"4","author":"Haque","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2022.108858_b0505","first-page":"1","article-title":"Efficient therapeutic function and mechanisms of human polyclonal CD8+ CD103+ Foxp3+ regulatory T cells on collagen-induced arthritis in mice","volume":"2019","author":"Sun","year":"2019","journal-title":"J Immunol. Res."},{"issue":"3","key":"10.1016\/j.intimp.2022.108858_b0510","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/annrheumdis-2018-214024","article-title":"Tolerising cellular therapies: what is their promise for autoimmune disease?","volume":"78","author":"Mosanya","year":"2019","journal-title":"Ann. Rheum Dis."},{"issue":"2","key":"10.1016\/j.intimp.2022.108858_b0515","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.transci.2012.06.007","article-title":"T regulatory cell separation for clinical application","volume":"47","author":"Di Ianni","year":"2012","journal-title":"Transfus. Apher. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2022.108858_b0520","doi-asserted-by":"crossref","first-page":"e15868","DOI":"10.1371\/journal.pone.0015868","article-title":"Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells","volume":"6","author":"Golovina","year":"2011","journal-title":"PLoS ONE"},{"issue":"83","key":"10.1016\/j.intimp.2022.108858_b0525","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001809","article-title":"Massive ex vivo expansion of human natural regulatory T cells (Tregs) with minimal loss of in vivo functional activity","volume":"3","author":"Hippen","year":"2011","journal-title":"Sci. Trans. Med."},{"issue":"21","key":"10.1016\/j.intimp.2022.108858_b0530","first-page":"4303","article-title":"Long-term prevention of chronic allograft rejection by regulatory T-cell immunotherapy involves host Foxp3-expressing T cells","volume":"121","author":"Pasquet","year":"2013","journal-title":"Blood. Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108858_b0535","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.smim.2006.01.004","article-title":"Antigen-specific regulatory T cells\u2014ex vivo expansion and therapeutic potential, in Seminars in immunology","volume":"18","author":"Masteller","year":"2006","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2022.108858_b0540","article-title":"Collagen II-primed Foxp3 transduced T cells ameliorate collagen-induced arthritis in rats: the effect of antigenic priming on T regulatory cell function","volume":"361\u2013371","author":"Zavvar","year":"2018","journal-title":"Iran J Allergy Asthma Immunol."},{"key":"10.1016\/j.intimp.2022.108858_b0545","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3389\/fimmu.2017.01517","article-title":"Engineering specificity and function of therapeutic regulatory T cells","volume":"8","author":"McGovern","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.108858_b0550","first-page":"3868","article-title":"Super-Treg: towards a new era of adoptive Treg therapy enabled by genetic modifications","volume":"11","author":"Amini","year":"2020","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2022.108858_b0555","doi-asserted-by":"crossref","first-page":"8140","DOI":"10.4049\/jimmunol.177.11.8140","article-title":"Gene therapy of arthritis with TCR isolated from the inflamed paw","volume":"177","author":"Fujio","year":"2006","journal-title":"J. Immunol."},{"issue":"45","key":"10.1016\/j.intimp.2022.108858_b0560","doi-asserted-by":"crossref","first-page":"19078","DOI":"10.1073\/pnas.0907396106","article-title":"Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis","volume":"106","author":"Wright","year":"2009","journal-title":"PNAS"},{"issue":"11","key":"10.1016\/j.intimp.2022.108858_b0565","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.4049\/jimmunol.1300024","article-title":"Engineered regulatory T cells coexpressing MHC class II: peptide complexes are efficient inhibitors of autoimmune T cell function and prevent the development of autoimmune arthritis","volume":"190","author":"Qian","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2022.108858_b0570","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.3389\/fimmu.2018.03180","article-title":"Lymphocytes in cellular therapy: functional regulation of CAR T cells","volume":"9","author":"Dwivedi","year":"2019","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2022.108858_b0575","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3390\/cancers9110150","article-title":"CAR-T cell therapy: From the bench to the bedside","volume":"9","author":"Golubovskaya","year":"2017","journal-title":"Cancers."},{"key":"10.1016\/j.intimp.2022.108858_b0580","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3389\/fimmu.2018.02359","article-title":"Chimeric antigen receptor (CAR) Treg: a promising approach to inducing immunological tolerance","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108858_b0585","doi-asserted-by":"crossref","first-page":"1700097","DOI":"10.1002\/biot.201700097","article-title":"Cancer Immunotherapy Using CAR-T Cells: From the Research Bench to the Assembly Line","volume":"13","author":"Gomes-Silva","year":"2018","journal-title":"Biotechnol. J."},{"issue":"1","key":"10.1016\/j.intimp.2022.108858_b0590","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/imr.12126","article-title":"CAR T cells: driving the road from the laboratory to the clinic","volume":"257","author":"Cheadle","year":"2014","journal-title":"Immunol. Rev."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2022.108858_b0595","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/tan.12822","article-title":"How antigen specificity directs regulatory T-cell function: self, foreign and engineered specificity","volume":"88","author":"Hoeppli","year":"2016","journal-title":"Hla."},{"key":"10.1016\/j.intimp.2022.108858_b0600","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.trsl.2017.06.009","article-title":"Antigen-specific regulatory T cells: are police CARs the answer?","volume":"187","author":"Dawson","year":"2017","journal-title":"Trans. Res."},{"key":"10.1016\/j.intimp.2022.108858_b0605","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fimmu.2019.00043","article-title":"Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity","volume":"10","author":"Romano","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2022.108858_b0610","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jim.2017.08.004","article-title":"Prediction of antibody structural epitopes via random peptide library screening and next generation sequencing","volume":"451","author":"Ibsen","year":"2017","journal-title":"J. Immunol. Methods."},{"issue":"7664","key":"10.1016\/j.intimp.2022.108858_b0615","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23270","article-title":"In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target","volume":"547","author":"Manguso","year":"2017","journal-title":"Nat."},{"issue":"2","key":"10.1016\/j.intimp.2022.108858_b0620","doi-asserted-by":"crossref","first-page":"e56246","DOI":"10.1371\/journal.pone.0056246","article-title":"Identification of novel autoantigen in the synovial fluid of rheumatoid arthritis patients using an immunoproteomics approach","volume":"8","author":"Biswas","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2022.108858_b0625","article-title":"Development of citrullinated-vimentin-specific CAR for targeting Tregs to treat autoimmune rheumatoid arthritis","author":"Raffin","year":"2018","journal-title":"Am Assoc Immnol."},{"issue":"1-3","key":"10.1016\/j.intimp.2022.108858_b0630","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2741\/1506","article-title":"Citrullinated proteins in rheumatoid arthritis","volume":"10","author":"Yamada","year":"2005","journal-title":"Front Biosci"},{"issue":"4","key":"10.1016\/j.intimp.2022.108858_b0635","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/eji.200838904","article-title":"Loss of FOXP3 expression in natural human CD4+ CD25+ regulatory T cells upon repetitive in vitro stimulation","volume":"39","author":"Hoffmann","year":"2009","journal-title":"Euro. J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2022.108858_b0640","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/ni.1774","article-title":"Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo","volume":"10","author":"Zhou","year":"2009","journal-title":"Nat. Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922003423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922003423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:46:57Z","timestamp":1761587217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922003423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":128,"alternative-id":["S1567576922003423"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108858","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapeutic potential of regulatory T (Treg) cells for rheumatoid arthritis: New insights and challenges","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108858"}}